Paris, France – February 19, 2026 – A pivotal moment has arrived for France’s medical cannabis industry. Key news emerged at Cannabis Europa Paris 2026. French authorities presented the first draft of a long-awaited reimbursement framework. This marks a significant step. It is crucial for moving France to a permanent medical cannabis market. This transition follows years of pilot programs. The event highlighted evolving European cannabis trends.
A Framework Emerges
French officials shared the draft on February 18. This private consultation involved industry stakeholders. The meeting was organized by the Direction Générale de la Santé (DGS) and the Direction de la Sécurité Sociale (DSS). These details were then shared with delegates the next morning. Cannabis Europa Paris served as the platform for this crucial information. Stephen Murphy, CEO of Prohibition Partners, noted how far Europe has come. He stated that medical cannabis is now seen as legitimate. It is actively being provided to patients. France’s discussions are now central to European conversations.
Key Details of the Draft
The proposed model establishes a tiered reimbursement structure. This structure is directly tied to the Haute Autorité de Santé’s (HAS) assessment. It evaluates each product’s therapeutic benefit. Coverage rates will vary. They can be set at 65%, 30%, 10%, or 0%. These levels correspond to major, moderate, minor, or insufficient benefit. However, these headline rates may not be the final picture for many patients. Many eligible patients suffer from long-term conditions. These qualify for ALD status. Thus, most could access cannabis medicines at 100% coverage. This aspect is still being finalized. Pricing will group medicines by product categories. Factors include pharmaceutical form, composition, and clinical traits. A single price will apply to each category. Prices will remain fixed for three years. They may be revised based on new clinical evidence. This regulatory news is a significant development.
Timeline and Next Steps
A consultation period follows the February 18 meeting. Stakeholders have three weeks to a month to submit comments. The draft text will undergo review. Regulatory decrees are expected to be formally adopted in June. Following this, companies can begin product registration. They will register with the French drug agency ANSM. The HAS will simultaneously resume its evaluation work. A final HAS opinion on reimbursement is anticipated around October or November 2026. Patients currently in the pilot program will remain covered. An extended scheme will run until December 31, 2026. This ensures continuity of care. The transition from pilot to permanent system is complex.
Industry and Patient Impact
Ludovic Rachou, President of UIVEC, highlighted the importance of the draft. UIVEC helped coordinate the reimbursement dossier submitted last September. He confirmed this meeting launches the consultation process. It addresses the final missing regulatory text. The decree is seen as the last obstacle. It stands between France and a fully operational medical cannabis market. The system aims for a permanent pharmaceutical regime. This would regulate access and pricing for the next decade. Such news is vital for industry events. It provides clear direction for businesses. For patients, it offers a path toward greater accessibility. This is a significant update in the ongoing cannabis news cycle.
Europe’s Evolving Landscape
France’s progress mirrors broader European momentum. Germany’s 2024 reforms have reshaped investment sentiment. Other countries are also evolving their cannabis policies. Cannabis Europa Paris 2026 gathers key figures. They discuss policy, healthcare, and investment. This includes policymakers, clinicians, and industry executives. The event provides a platform for critical dialogue. It examines France’s transition. It also explores broader European regulatory frameworks. The goal is to advance evidence-based policy. This ultimately aims to improve patient access across the continent. The industry is watching these developments closely.
